RxDoctor Payments Data

Ivan Luptak, MD

Cardiovascular Disease · Boston, MANPI 1962650853

Payments from drug & device makers

What this record shows

That places this record below the midpoint for cardiovascular disease clinicians in MA, where the typical reported total is $954.

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$279,838in research payments, 2019–2025

Across 2 payments — averaging $139,919 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$280K

How this compares

$0 in reported general payments places this provider in the 0th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$27,012
Medicare patients
169
Services billed
284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin97$81,420
EntrestoSacubitril/Valsartan23$28,551
FarxigaDapagliflozin Propanediol18$14,938
Metoprolol Succinate55$1,107
Atorvastatin Calcium35$448
Torsemide13$378
Losartan Potassium45$351
Spironolactone43$342
Furosemide38$324
Lisinopril31$186
Carvedilol22$167
Amlodipine Besylate19$92

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →